The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Ethical and legal framework and regulation for off-label use: European perspective
Open accessAbstract
For more than 20 years the off-label use of drugs has been an essential part of the ethical and legal considerations regarding the international regulation of drug licensing. Despite a number of regulatory initiatives in the European Union, there seems to remain a largely unsatisfactory situation following a number of critical descriptions and statements from actors in the field. The present article gives an overview of the ethical and legal framework and developments in European countries and identifies existing problems and possible pathways for solutions in this important regulatory area. In addition to the presentation of the ethical and legal foundations, some attention is given to criticisms from medical practitioners to the current handling of off-label drug use. The review also focuses on the situation confronted by patients and physicians when off-label prescriptions are necessary. Through legal descriptions from a number of countries, possible solutions for future discussion of European health care policy are selected and explained.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The fragmented nature of international regulatory guidelines further complicates their integration into clinical practice.158”
From Off-label and repurposed use of disulfiram beyond alcohol dependence: A systematic review of clinical and preclinical evidence (2026) · cites this paper as [158]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the European Union, for example, off-label use is not regulated centrally; each Member State has developed its own policy.4,158”
From Off-label and repurposed use of disulfiram beyond alcohol dependence: A systematic review of clinical and preclinical evidence (2026) · cites this paper as [158]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Off label and unlicensed drug use among French office based paediatricians
Chalumeau, M. (2000) · Archives of Disease in Childhood · doi:10.1136/adc.83.6.502 · Cited by 169
Defining off-label and unlicensed use of medicines for children: Results of a Delphi survey
Neubert, A. C., Wong, I. C. K., Bonifazi, A., Catapano, M., Felisi, M., Baiardi, P., Giaquinto, C., Knibbe, C. A. J., Sturkenboom, M., Ghaleb, M. A., et al. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.09.007 · Cited by 120
Casali, P. G. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm517 · Cited by 80
France's New Framework for Regulating Off-Label Drug Use
Emmerich, J., Dumarcet, N., & Lorence, A. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1208347 · Cited by 73
Calkins, D. R., Fernandopulle, R., & Marino, B. S. (1995) · Medical Entomology and Zoology · Cited by 59
Paediatric clinical pharmacology—at the beginning of a new era
Hoppu, K. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0390-5 · Cited by 55
Off-label, off-limits? Parental awareness and attitudes towards off-label use in paediatrics
Lenk, C., Koch, P., Zappel, H., & Wiesemann, C. (2009) · European Journal of Pediatrics · doi:10.1007/s00431-009-0956-6 · Cited by 40
Self-citationBücheler, R., Meisner, C., Kalchthaler, B., Mohr, H., Schröder, H., Mörike, K., Schwoerer, P., Schwab, M. G., & Gleiter, C. H. (2002) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-2002-35819 · Cited by 38
Reforming Off-Label Promotion to Enhance Orphan Disease Treatment
Liang, B. A., & Mackey, T. K. (2010) · Science · doi:10.1126/science.1181567 · Cited by 25
Off-Label Drug Use in Paediatrics: A World-Wide Problem
Lenk, C. (2012) · Current Drug Targets · doi:10.2174/138945012800675759 · Cited by 21
Self-citation
Research works printed but not linked: 2
- [5]Bücheler R Meisner C Kalchthaler B “Off-label” prescribing of drugs in the ambulatory care of children and adolescents Dtsch Med Wochenschr 2002 127 48 2551 2557 German 12457324
- [31]Deutsch E Spickhoff A Medizinrecht [Medical Law] 6th ed Berlin/Heidelberg Springer 2008 German
Cited by
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., & Einav, S. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.03.005 · Cited by 1,160
Schrier, L., Hadjipanayis, A., Stiris, T., Ross-Russell, R. I., Valiulis, A., Turner, M. A., Zhao, W., Cock, P. A. J. G. D., de Wildt, S. N., Allegaert, K., et al. (2020) · European Journal of Pediatrics · doi:10.1007/s00431-019-03556-9 · Cited by 146
El‐Qutob, D. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8490-y · Cited by 96
Verbaanderd, C., Rooman, I., Meheus, L., & Huys, I. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01664 · Cited by 82
Off-Label Medication: From a Simple Concept to Complex Practical Aspects
Rusz, C.-M., Ősz, B.-E., Jîtcă, G., Miklos, A., Bătrînu, M.-G., & Imre, S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph181910447 · Cited by 58
COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus
Jan, H., Faisal, S., Khan, A., Khan, S., Usman, H., Liaqat, R., & Shah, S. A. (2020) · Discoveries · doi:10.15190/d.2020.5 · Cited by 66
Pharmacologic Prevention of Migraine: A Narrative Review of the State of the Art in 2018
Loder, E., & Rizzoli, P. B. (2018) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13375 · Cited by 58
DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment
Bernhardt, D., König, L., Grosu, A., Rieken, S., Krieg, S. M., Wick, W., Wiestler, B., Schmidt‐Graf, F., Sahm, F., Gempt, J., et al. (2022) · Strahlentherapie und Onkologie · doi:10.1007/s00066-022-01973-8 · Cited by 48
Vilhelmsson, A., Davis, C., & Mulinari, S. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1001945 · Cited by 45
IMI – Industry Guidelines and Ethical Considerations for Myopia Control Report
Jones, L., Drobe, B., González‐Méijome, J. M., Gray, L. S., Kratzer, T., Newman, S., Nichols, J. J., Ohlendorf, A., Ramdass, S., Santodomingo‐Rubido, J., et al. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-25963 · Cited by 42
Measured Glomerular Filtration Rate: The Query for a Workable Golden Standard Technique
Speeckaert, M. M., Seegmiller, J. C., Glorieux, G., Lameire, N. H., Biesen, W. V., Vanholder, R. C., & Delanghe, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11100949 · Cited by 40
Aagaard, L., & Kristensen, K. (2018) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-018-0646-4 · Cited by 38
Li, X., Zheng, S., Gu, J.-H., Huang, T., Liu, F., Ge, Q., Liu, B., Li, C., Yi, M., Qin, Y., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.571906 · Cited by 40
It is time to review how unlicensed medicines are used
Sutherland, A. B., & Waldek, S. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1886-z · Cited by 26
Ghabri, S., Autin, E., Poullié, A.-I., & Josselin, J. M. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0602-5 · Cited by 25
Degrassat-Théas, A., Bocquet, F., Sinègre, M., Peigné, J., & Paubel, P. (2015) · Health Policy · doi:10.1016/j.healthpol.2015.09.003 · Cited by 25
Challis, P., Nydert, P., Håkansson, S., & Norman, M. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.7269 · Cited by 25
Jîtcă, C.-M., Jîtcă, G., Ősz, B.-E., Puşcaş, A., & Imre, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041306 · Cited by 23
Nayroles, G., Frybourg, S., Gabriel, S., Kornfeld, A., Antoñanzas, F., Espín, J., Jommi, C., Martini, N., de Pouvourville, G., Tolley, K. H., et al. (2017) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2017.1298190 · Cited by 23
Löblová, O., Csanádi, M., Ozierański, P., Kaló, Z., KING, L. P., & McKee, M. (2019) · Health Policy · doi:10.1016/j.healthpol.2019.05.021 · Cited by 21
Nguyen, N. T., Rakow, T., Gardner, B., & Dommett, E. J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0244865 · Cited by 18
Sweileh, W. M. (2021) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-210012 · Cited by 18
Management guideline for the off-label use of medicine in China (2021)
Zuo, W., Sun, Y., Liu, R., Du, L., Yang, N., Sun, W., Wang, P., Tang, X., Liu, Y., Ma, Y., et al. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2120468 · Cited by 17
Ladanie, A., Ioannidis, J. P. A., Stafford, R. S., Ewald, H., Bucher, H. C., & Hemkens, L. G. (2017) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2017.11.006 · Cited by 17
Schubert, N. A., Chen, C. Y., Rodríguez, A. I. E., Köster, J., Dowless, M. S., Pfister, S. M., Shields, D. J., Stancato, L. F., Vassal, G., Caron, H. N., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.028 · Cited by 16
Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology
Löblová, O., Csanádi, M., Ozierański, P., Kaló, Z., KING, L. P., & McKee, M. (2019) · Health Policy · doi:10.1016/j.healthpol.2019.05.012 · Cited by 15
Paddock, S., Abedtash, H., Zummo, J., & Thomas, S. (2019) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-019-0983-9 · Cited by 16
Schubert, N. A., Lowery, C. D., Bergthold, G., Köster, J., Eleveld, T. F., Rodríguez, A. I. E., Jones, D., Vassal, G., Stancato, L. F., Pfister, S. M., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.01.027 · Cited by 12
Ketamine for the Treatment of Depression
Kraus, C., Lanzenberger, R. R., & Kasper, S. F. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1770 · Cited by 11
Minghetti, P., Lanati, E. P., Godfrey, J., Solà-Morales, O., Wong, O., & Selletti, S. (2017) · Medicine Access Point of Care · doi:10.5301/maapoc.0000016 · Cited by 10
Bevacizumab for eye diseases – Legal, regulatory, and ethical overview
Jose, V. M., Radhakrishna, S., Pipalava, P., & Singh, I. (2019) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_413_19 · Cited by 10
Off-label drugs in palliative care: a Group Delphi treatment recommendation process
Rémi, C., Weingärtner, K., Hagemann, V., Bausewein, C., & Hodiamont, F. (2020) · BMJ Supportive & Palliative Care · doi:10.1136/bmjspcare-2019-002165 · Cited by 9
Current regulatory approaches for accessing potential COVID-19 therapies
Halimi, V., Daci, A., Stojanovska, S., Panovska-Stavridis, I., Stevanovic, M., Filipče, V., & Grozdanova, A. (2020) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-020-00222-6 · Cited by 9
Zuckerman, S., Bar‐Lavie, Y., Niv, Y., Arad, D., & Lev, S. (2021) · Journal of Medical Ethics · doi:10.1136/medethics-2020-106783 · Cited by 9
Landscape of early clinical trials for childhood and adolescence cancer in Spain
Bautista, F. J., Gallego, S., Cañete, A., Mora, J., de Heredia, C. D., Cruz, O., Fernández, J. M., Rives, S., Madero, L., Castel, V., et al. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1421-9 · Cited by 7
Marešová, P., Klímová, B., & Kuča, K. (2016) · Applied Economics · doi:10.1080/00036846.2015.1125433 · Cited by 7
Reflections on COVID-19, Insurance, Business Interruption, Systemic Risk, and the Future
Jerry, R. H. (2021) · ICADE Revista de la Facultad de Derecho · doi:10.14422/icade.i110.y2020.007 · Cited by 6
Meng, M., Hu, J., Lei, W., Tian, M., Liu, X., Lu, Y., Liu, E., Zhang, S. J., Han, Z., Li, Q., et al. (2024) · Translational Pediatrics · doi:10.21037/tp-24-198 · Cited by 6
Drenska, M., & Getov, I. N. (2017) · Acta Medica Bulgarica · doi:10.1515/amb-2017-0003 · Cited by 6
Recommendations for Off-Label Drug Use in Ophthalmology in China: A Clinical Practice Guideline
Li, G., Wang, N., Zhang, Y., Wei, W., Lu, H., Zhai, S., & Zhang, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.919688 · Cited by 7
Glassberg, M. K., Csete, I., & Toonkel, R. L. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.01.051 · Cited by 6
Off-Label Treatment in Inflammatory Skin Diseases—European Point of View
Sternicka, J., Nowicki, R. J., Bieniaszewski, L., & Purzycka-Bohdan, D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14072376 · Cited by 5
Boßung, V., Rath, W. H., Rody, A., & Schwarz, C. (2021) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-021-06079-7 · Cited by 5
Individualized and innovative gender healthcare for transgender and nonbinary youth
Clark, D. B. A., Metzger, D. L., Pang, K. C., Amand, C. S., & Khatchadourian, K. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01113-z · Cited by 6
Legislation, regulation and policies issues of orphan drugs in developed countries from 2010 to 2016
Marešová, P., Klímová, B., & Kuča, K. (2018) · Journal of Applied Biomedicine · doi:10.1016/j.jab.2018.04.002 · Cited by 5
Off-label medications in the treatment of hospitalized children with atopic dermatitis
Niedźwiedź, M., Skibińska, M., Narbutt, J., & Lesiak, A. (2022) · Advances in Dermatology and Allergology · doi:10.5114/ada.2022.119967 · Cited by 5
Dual Use in Neuroscientific and Neurotechnological Research: A Need for Ethical Address and Guidance
Giordano, J. J., & Evers, K. (2018) · Emerald Group Publishing Limited eBooks · doi:10.1108/s2398-601820180000004009 · Cited by 5
The Expanding Role of Omalizumab: From Food Allergy to Drug Desensitization
Kosztulska, B., Rydzyńska, M., Bartuzi, Z., Grześk-Kaczyńska, M., & Ukleja-Sokołowska, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167868 · Cited by 4
The eyes of the beholder: Perceived barriers to successful drug repurposing
Petykó, Z. I., Hosszú, D., Csanádi, M., Gyöngyösi, K., Obeng, G. D., Ameyaw, D., Dóczi, T. I., Kaló, Z., Lo, D. C., van der Meer, H. G., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70243 · Cited by 4
Cheung, K., Teichert, M., Moll, H. A., Stricker, B. H. C., & Visser, L. E. (2018) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-018-0717-6 · Cited by 4
Barbosa, C., & Matos, M. F. (2016) · CADERNOS IBERO-AMERICANOS DE DIREITO SANITÁRIO · doi:10.17566/ciads.v5i3.329 · Cited by 4
Off-Label Medicines Use: Complex Problem of Modern Clinical Practice
Gilyarevskiy, S. R. (2020) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2020-04-14 · Cited by 4
Gallitelli, V., Franco, R., Guidi, S., Zaami, S., Parasiliti, M., Vidiri, A., Perelli, F., Plotti, F., Eleftheriou, G., Mattei, A., et al. (2025) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.70076 · Cited by 3
Off-label use of medicines in South Africa: a review
Ngcobo, N. N., & Mathibe, L. J. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03476-4 · Cited by 8
Ensayos clínicos precoces en oncología pediátrica en España: una perspectiva nacional
Bautista, F. J., Gallego, S., Cañete, A., Mora, J., de Heredia, C. D., Cruz, O., Fernández, J. M., Rives, S., Berlanga, P., Hladun, R., et al. (2017) · Anales de Pediatría · doi:10.1016/j.anpedi.2016.07.007 · Cited by 3
Steger, F., Gierschik, P., & Rubeis, G. (2018) · Der Onkologe · doi:10.1007/s00761-018-0445-5 · Cited by 3
Drenska, M., Grigorova, V., Elitova, S., Naseva, E., & Getov, I. N. (2019) · Drugs & Therapy Perspectives · doi:10.1007/s40267-019-00638-4 · Cited by 3
A RETROSPECTIVE STUDY: THE OFF-LABEL USE OF ANTICONVULSANTS AT A PRIVATE HOSPITAL IN INDONESIA
Rahajeng, B., Ikawati, Z., Andayani, T. M., & Dwiprahasto, I. (2018) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2018v10i5.25388 · Cited by 3
Benkő, B.-M., De Brito Parreirinha, N. S., Sebe, I., & Zelkó, R. (2026) · iScience · doi:10.1016/j.isci.2026.115441 · Cited by 2
Suponeva, N. A., & Гришина, Д. А. (2015) · Neuromuscular Diseases · doi:10.17650/2222-8721-2015-5-4-16-23 · Cited by 2
Faust, A., Woydack, L., & Strech, D. (2023) · Health Policy · doi:10.1016/j.healthpol.2023.104752 · Cited by 3
Ethische Fragen in der Neuroradiologie
Ulmer, S. (2016) · Springer eBooks · doi:10.1007/978-3-662-49916-0_12 · Cited by 2
Bouvenot, G., Juillet, Y., Saint-Pierre, A., & Serre, M.-P. (2018) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30181-5 · Cited by 15
Dhupkar, P. M., & Mukherjee, S. (2021) · Clinical Ethics · doi:10.1177/14777509211011431 · Cited by 2
The Challenges of Crizotinib Treatment in a Child With Anaplastic Large Cell Lymphoma
Vanheeswijck, L., Verlooy, J., de Vijver, E. V., Bervoets, A., Balliauw, K., Schepens, T., Norga, K., & van Heerden, J. (2021) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-26.6.647 · Cited by 2
Moxifloxacin-induced insomnia with psychotic episodes in a toddler: a case report
Getova-Kolarova, V., Hababa-Ivanova, I., & Georgieva, N. (2025) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2025-004600 · Cited by 1
Off-label treatment of atopic dermatitis and psoriasis
Sternicka, J., Bieniaszewski, L., Nowicki, R. J., & Purzycka-Bohdan, D. (2026) · Journal of Dermatological Treatment · doi:10.1080/09546634.2026.2617768 · Cited by 1
Perception of oncology practitioners towards off-label use of anticancer medicines in Singapore
Saiyed, M., Ong, P. S., & Chew, L. S. T. (2017) · Journal of Pharmaceutical Health Services Research · doi:10.1111/jphs.12175 · Cited by 1
Appropriate off-label drug use
Lee, S. M. (2018) · Journal of Korean Medical Association · doi:10.5124/jkma.2018.61.3.140 · Cited by 1
Regulatory Aspects of Genomic Medicine and Pharmacogenomics
Ghirtis, K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813695-9.00020-0 · Cited by 1
Ethical Issues Regarding Off - Label Administration of Antibiotics
Hunea, I. M., Luca, C. M., Eşanu, I., Hurmuzache, M., Manciuc, C. D., Dima, I., Vâţă, A., & Miftode, E. G. (2020) · Journal of Intercultural Management and Ethics · doi:10.35478/jime.2020.1.04 · Cited by 1
A Systematic Review on the Potency and How Safe Chloroquine is for the Treatment of COVID-19Preprint
Tunde, A. A. (2020) · doi:10.21467/preprints.58 · Cited by 1
Klinische Prüfungen mit Arzneimitteln in der Schwangerschaft
Knop, S. (2015) · Göttinger Schriften zum Medizinrecht · doi:10.17875/gup2015-885
Shelf life of diluted human interferon-α for veterinary clinical use
Amadori, M., & Fiorentini, G. (2017) · Biologicals · doi:10.1016/j.biologicals.2017.03.006
A European proposal to regulate off-label prescription in China
Raposo, V. L. (2020) · Asia Europe Journal · doi:10.1007/s10308-020-00569-0
Tridente, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809400-6.00029-9
Cancer, the Media and Dealing with Knowledge
Steger, F., & Schochow, M. (2021) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-63749-1_8
THE ETHICS OF PRESCRIBING OFF-LABEL DRUGS IN CHILDREN.THE DILEMMA OF SILDENAFIL
Sztankovszky, L.-Z., Iorga, M., Gheonea, C., & Russu, G. (2015) · Romanian Journal of Pediatrics · doi:10.37897/rjp.2015.2.4
Off-label Prescription and Challenges in Clinical Practice: An Abridged Review
(2020) · AMEI's Current Trends in Diagnosis & Treatment · doi:10.5005/jp-journals-10055-0098
Kurniawan, A. H., Yusmaniar, Y., & Fajri, P. (2021) · JPSCR Journal of Pharmaceutical Science and Clinical Research · doi:10.20961/jpscr.v6i2.43256
UPDATE SOBRE OS CUIDADOS PALIATIVOS NO CONTEXTO DA COVID-19
UNICEPLAC, C. U. D. P. C. A. D. S. –., QUEIROZ, E. C. D., Carvalho, V. P., Mendonça, A. B. L., Moreira, B. C., Kuster, B. P., SANTOS, E. C. A. D., Pagnoca, É. V. R. G., MOREIRA, F. B. D. S., Ribeiro, H. L. S., et al. (2022) · Editora UNINGÁ eBooks · doi:10.46311/978-65-991603-9-4
Early clinical trials in paediatric oncology in Spain: A nationwide perspective
Bautista, F. J., Gallego, S., Cañete, A., Mora, J., de Heredia, C. D., Cruz, O., Fernández, J. M., Rives, S., Berlanga, P., Hladun, R., et al. (2017) · Anales de Pediatría (English Edition) · doi:10.1016/j.anpede.2016.07.007
COVID-19 off-label uses of medicines: the role of civil liability and regulation
Parziale, A. (2023) · The Geneva Papers on Risk and Insurance Issues and Practice · doi:10.1057/s41288-023-00302-z
Moreno, Y. B. B. (2023) · Revista de derecho y genoma humano: genética, biotecnología y medicina avanzada = Law and the human genome review: genetics, biotechnology and advanced medicine · doi:10.14679/2031
Pengetahuan dan Persepsi Apoteker Terhadap Penggunaan Obat Off-Label di Indonesia
Ramdini, D. A., Sarmoko, S., Rahayu, I. D., Iqbal, M., Triyandi, R., & Destiani, D. P. (2023) · Indonesian Journal of Pharmacy and Natural Product · doi:10.35473/ijpnp.v6i01.2219
Profil Penggunaan Obat Off-Label pada Pasien Obstetri Ginekologi di RSUD Blambangan Banyuwangi
Norcahyanti, I., Rachmawati, S., & Pertiwi, S. P. (2023) · Jurnal Pharmascience · doi:10.20527/jps.v10i2.17698
A Mini-Theory of Hidden Marketing Strategy as Competitive Advantage
(2024) · Quality - Access to Success · doi:10.47750/qas/25.200.07
Off-Label Treatment of Alopecia Areata—Retrospective Study
Sternicka, J., Bieniaszewski, L., Krzyżaniak, N., Nowicki, R. J., & Purzycka-Bohdan, D. (2026) · Biomedicines · doi:10.3390/biomedicines14020367 · Cited by 1
Mysore, V. N., Arora, G., Chandrashekar, B. S., Khunger, N., Dixit, R., Arsiwala, S., Dashore, S., Shah, S., Salim, T., Vasudevan, B., et al. (2026) · Journal of Cutaneous and Aesthetic Surgery · doi:10.25259/jcas_337_2025
Personnes vulnérables et essais cliniques : réflexions en droit européen
Gennet, É. (2018) · theses.fr (ABES) · doi:10.70675/c1df7528z46f0z468azbc36z1acd530de0e6 · Cited by 3
Tranexamic acid in prehospital emergency medicine: Evidence and availability in Vojvodina
Pešić, I., Kasap, A., & Zinijakov, M. (2026) · ABC - časopis urgentne medicine · doi:10.5937/abc2601034p
Xia, M., Duan, J., Chen, N., Zhou, W., Zhang, N., Feng, M., Sun, Y., & Luan, Y. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s580802
Joksimovic, J., Spasic, D. M., Kukurić, M., & Bajčetić, M. (2026) · Children · doi:10.3390/children13040536
Development and Validation of a Rapid Benefit–Risk Assessment Index for Pediatric Off‐Label Drug Use
Li, X., Xu, Y., Jin, G., Jiang, W., Chen, Z., Zheng, Z., Wang, X., Mo, X., Liu, X., Zhou, B., et al. (2026) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70177
Metadata
- Authors
- Lenk, C., & Duttge, G.
- Affiliations
- Universität Ulm (DE)
- University of Göttingen (DE)
- Corresponding author
- Lenk, Christian
- Venue
- Therapeutics and Clinical Risk Management
- Publisher
- Informa UK Limited
- Published
- 2014-07
- Volume
- 10
- Pages
- 537
- ISSN
- 1176-6336 (ISSN-L)
- 1178-203X
- PMC
- PMC4103928
- OpenAlex
- W2047986597
- Cited by
- 96
- References
- 20
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 3 · 2023: 6 · 2022: 6 · 2021: 12 · 2020: 13 · 2019: 7 · 2018: 12 · 2017: 11 · 2016: 5 · 2015: 7
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Therapeutics and Clinical Risk Management (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by-nc)
- GRO (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- off-label drug use, drug regulation, drug approval, pharmaceutical ethics, medical law, European Union health policy, patient rights, comparative health law
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.